Mark O'Connor

23PUBLICATIONS
192CO-AUTHORS
Molecular targetsInnate immunityPredictive and prognostic markersPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Dec 29, 2025
Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in BRCA mutant cancer cells.

Jonathan Ribeiro, Kjetil Hansen, Lotte van Beek

|Oct 28, 2025
Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling.

Anish Thomas, Nobuyuki Takahashi, Lenka Oplustil O'Connor

|Oct 09, 2025
Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair.

Giuditta Illuzzi, Alessandro Galbiati, Anna D Staniszewska

|May 17, 2025
The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study.

Timothy A Yap, Patricia LoRusso, Rowan E Miller

|May 13, 2025
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.

Jean E Abraham, Lenka Oplustil O'Connor, Louise Grybowicz

|Mar 11, 2025
Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Breast Cancer.

Flaminia Pedretti, Mohmed Abdalfttah, Benedetta Pellegrino

Pageof 4

Frequent Collaborators

5 joint publications

Giuditta Illuzzi

5 joint publications

Josep V Forment

4 joint publications

Violeta Serra

4 joint publications

Gareth Hughes